Supreme Court Turns Down Athena v. Allergan; 'Torrent' Of Suits To Come?
This article was originally published in The Rose Sheet
Following the recommendation of Solicitor General Donald Verrilli, the Supreme Court has declined to review Allergan v. Athena Cosmetics, a case examining if the Federal Food, Drug and Cosmetic Act preempts an unfair competition claim in California characterizing Athena's RevitaLash products as unapproved drugs. Athena predicts a "torrent of novel and disruptive litigation" could ensue.
You may also be interested in...
Athena Cosmetics’ new RevitaLash hair-care line includes Hair Volume Enhancing Foam, made with the same BioPeptin Complex that replaced a prostaglandin in the company’s original RevitaLash Advanced Eyelash Conditioner. More cosmetic launch news in brief.
Marketers of cosmetic lash enhancers that haven’t abandoned prostaglandin analogs in favor of peptides or botanical extracts should take heed of a proposed class action against Rodan + Fields in California’s Northern District. Plaintiffs say they would not have purchased the firm’s Lash Boost and suffered alleged adverse effects if they’d been properly informed about product risks.
Amarin's petition to the Federal Circuit Court to direct ITC to investigate its complaint that some omega-3 ingredients are unapproved drugs leans on Supreme Court decisions that compliance with FDA regulations in cosmetic and food labeling does not preclude litigation alleging the information rendered a product an unapproved drug or represented false advertising.